Heike Keilhack, Ph.D.

Chief Scientific Officer

Dr. Keilhack is an accomplished cancer biologist with rich experience in cell biology, animal models of cancer, pharmacology and translational medicine with over 15 years of experience in oncology drug discovery in both small biotechnology companies and large pharmaceutical companies. Prior to joining Ribon, Dr. Keilhack was Senior Director of Biology at Epizyme where, among other responsibilities, she was the project leader for the company’s EZH2 inhibitor program, tazemetostat, which was FDA-approved in 2020 as Tazverik^®. Before that, she was a research fellow at Merck and the biology project lead for the company’s clinical stage AKT inhibitor, MK-2206. Dr. Keilhack serves on the board of directors of Civetta Therapeutics.

Dr. Keilhack received her Ph.D. in Biochemistry at Friedrich Schiller University of Jena (Germany) and completed postdoctoral training at the Harvard Medical School. She earned a B.S. in Biochemistry at Martin Luther University of Halle-Wittenberg (Germany).